Clinical expectations for BCR-ABL monitoring have evolved over time both in response to more sensitive tests being developed and new treatments and management approaches emerging.
Largely in response to these medical advances, many CML patients have been able to successfully manage their diseases over time, as evidenced by increasing long-term survival rates. Chronic management of an increasing population of CML patients, however, places unique pressure on supporting laboratories, requiring that testing become sensitive enough to support a broad spectrum of clinical decisions while also being scalable to accommodate an ever-increasing number of tests.
This on-demand webinar from Asuragen discusses how the CE-IVD-certified QuantideX qPCR BCR-ABL IS Kit can overcome challenges in CML monitoring, providing a simple, sensitive, and scalable approach to BCR-ABL monitoring that meets today’s clinical expectations for testing.
Hosted by Justin T. Brown, principal scientist of research and development at Asuragen, the webinar covers:
Offered Free by: Asuragen
See All Resources from: Asuragen